2025
SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women This statement was endorsed by the Heart Failure Society of America (HFSA)
Baron S, Chou J, Shah T, Vest A, Abbott J, Alasnag M, Aurigemma C, Barbato E, Bellumkonda L, Bortnick A, Chieffo A, van Geuns R, Grines C, Halvorsen S, Hassager C, Kapur N, Naidu S, Ng V, Saw J, Lansky A. SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women This statement was endorsed by the Heart Failure Society of America (HFSA). Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 102150. DOI: 10.1016/j.jscai.2024.102150.Peer-Reviewed Original ResearchHeart Failure Society of AmericaCardiogenic shockWomen's cardiovascular healthConsensus statementSex-based disparitiesExpert consensus statementCardiovascular healthCardiovascular disease statesTreatment of CSTreatment of womenCardiovascular diseasePoor outcomeWomenDisparitiesSociety of AmericaDisease statesCS treatmentTreatmentPracticeHealthCliniciansSCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women.
Baron S, Chou J, Shah T, Vest A, Abbott J, Alasnag M, Aurigemma C, Barbato E, Bellumkonda L, Bortnick A, Chieffo A, van Geuns R, Grines C, Halvorsen S, Hassager C, Kapur N, Naidu S, Ng V, Saw J, Lansky A. SCAI/EAPCI/ACVC Expert Consensus Statement on Cardiogenic Shock in Women. EuroIntervention 2025 PMID: 40387531, DOI: 10.4244/eij-d-24-01126.Peer-Reviewed Original ResearchWomen's cardiovascular healthCardiogenic shockConsensus statementSex-based disparitiesCardiovascular healthExpert consensus statementCardiovascular disease statesTreatment of CSCardiovascular diseaseTreatment of womenWomenPoor outcomeDisparitiesDisease statesCS treatmentTreatmentPracticeHealthCliniciansA Survey for Human Tissue-Level Determinants of CAV1 Regulation and Function
Jiménez-Jiménez V, Sánchez-Cabo F, Schwartz M, Sánchez-Álvarez M, del Pozo M. A Survey for Human Tissue-Level Determinants of CAV1 Regulation and Function. International Journal Of Molecular Sciences 2025, 26: 3789. PMID: 40332409, PMCID: PMC12027754, DOI: 10.3390/ijms26083789.Peer-Reviewed Original ResearchConceptsGenotype-Tissue ExpressionTranscript levelsProtein-coding genesRNA-seq datasetsUpstream regulatory networkCell type proportionsInter-species comparisonsTissue-specific correlationsChromatin modifiersRegulatory networksPRC2 complexTissue-specific influencesCav1Complexity of human tissuesPhysiological regulationHuman tissuesPhysiological conditionsRegulationMetabolic stimuliCAV1 levelsDisease statesTissue dataInfiltration of immune cellsCellsChromatinSculpting excitable membranes: voltage-gated ion channel delivery and distribution
Tyagi S, Higerd-Rusli G, Akin E, Waxman S, Dib-Hajj S. Sculpting excitable membranes: voltage-gated ion channel delivery and distribution. Nature Reviews Neuroscience 2025, 26: 313-332. PMID: 40175736, DOI: 10.1038/s41583-025-00917-2.Peer-Reviewed Original ResearchConceptsNeuronal compartmentsPeripheral nervous system neuronsIon channel localizationNervous system neuronsMembrane ion channelsIon channel traffickingChronic painNeuronal excitabilityPotential therapeutic targetChannel traffickingIon channel distributionSystem neuronsChannel localizationNeuronal activityTherapeutic targetIon channelsTarget membrane insertionPost-translational modificationsDistal neuronal compartmentsDisease statesNeuronal homeostasisVesicular sortingDiseaseSpatiotemporal regulationChannel deliveryThe 2024 US Medical Eligibility Criteria for Contraceptive Use: Application to Practice in the Care of Patients With Cardiac Disease
Shapero K, Madden T. The 2024 US Medical Eligibility Criteria for Contraceptive Use: Application to Practice in the Care of Patients With Cardiac Disease. Circulation Research 2025, 136: 566-582. PMID: 40080533, DOI: 10.1161/circresaha.125.325682.Peer-Reviewed Original ResearchConceptsCardiac disease statesCardiac diseaseIntrauterine deviceMedical Eligibility Criteria for Contraceptive UseContraceptive methodsUS Medical Eligibility CriteriaContraceptive useEffective reversible contraceptive methodsProgestin-only methodsMedical Eligibility CriteriaAssociated with increased riskReversible contraceptive methodsAcquired heart diseaseUS Centers for Disease Control and PreventionDisease statesCenters for Disease Control and PreventionDisease Control and PreventionContraceptive counselingControl and PreventionMaternal mortalityCare of patientsUnplanned pregnancyEligibility criteriaPatientsHeart disease
2024
Worldwide Clinical and Real-World Exposure to Baricitinib
Vleugels R, Craiglow B, Mostaghimi A, Olsen E, Sontag A, Denning K, Somani N, Hordinsky M. Worldwide Clinical and Real-World Exposure to Baricitinib. SKIN The Journal Of Cutaneous Medicine 2024, 8: s501. DOI: 10.25251/skin.8.supp.501.Peer-Reviewed Original ResearchLength of therapyClinical trialsAtopic dermatitisTreated with baricitinibAverage length of therapyAge 2 yearsJuvenile idiopathic arthritisYears of ageMonths of ageBaricitinib doseAverage daily doseYrs of agePediatric patientsAcute infectious diseaseDaily doseCOVID-19 infectionAlopecia areataJAK inhibitorsHospitalized patientsIdiopathic arthritisBaricitinibPatientsBlind trialRheumatoid arthritisDisease statesClindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.
Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.Peer-Reviewed Original ResearchAcne vulgarisTreatment of acne vulgarisApplication of clindamycinCutaneous bacterial infectionsAntibiotic treatment efficacyTopical clindamycinTopical agentsOral treatmentClindamycinSystemic agentsMultiple disease statesPharmacokinetic profileTreatment efficacyAntibiotic resistanceBacterial infectionsAntibiotic mechanismsTherapeutic valueRelevance to cliniciansDisease statesDermatologyLincosamide antibioticsAnti-inflammatoryGram-positiveAnaerobic bacteriaAcneIdentifying topologically associating domains using differential kernels
Maisuradze L, King M, Surovtsev I, Mochrie S, Shattuck M, O’Hern C. Identifying topologically associating domains using differential kernels. PLOS Computational Biology 2024, 20: e1012221. PMID: 39008525, PMCID: PMC11249266, DOI: 10.1371/journal.pcbi.1012221.Peer-Reviewed Original ResearchConceptsTopologically associating domainsHi-C mapsFalse discovery rateChromatin conformation capture techniquesEnhancer-promoter interactionsLow false discovery rateSelf-interacting regionsStructure of chromatinRegulate gene expressionAverage contact probabilitiesHi-CLocus IDNA transcriptionGene expressionChromatinDiscovery rateContact probabilityBiological phenomenaState-of-the-artKernel-based techniqueComputer visionReplicationCorrelated changesDisease statesCapture techniquesSingle‐Cell Patch‐Clamp/Proteomics of Human Alzheimer's Disease iPSC‐Derived Excitatory Neurons Versus Isogenic Wild‐Type Controls Suggests Novel Causation and Therapeutic Targets
Ghatak S, Diedrich J, Talantova M, Bhadra N, Scott H, Sharma M, Albertolle M, Schork N, Yates J, Lipton S. Single‐Cell Patch‐Clamp/Proteomics of Human Alzheimer's Disease iPSC‐Derived Excitatory Neurons Versus Isogenic Wild‐Type Controls Suggests Novel Causation and Therapeutic Targets. Advanced Science 2024, 11: e2400545. PMID: 38773714, PMCID: PMC11304297, DOI: 10.1002/advs.202400545.Peer-Reviewed Original ResearchAbundance of individual proteinsIsogenic wild-type controlsSingle-cell (scHuman AD brainsWild-type controlsSingle-cellAlzheimer's diseaseMulticellular organismsSingle-cell physiologyAD brainTherapeutic targetIndividual proteinsProteomic informationGenetic mutationsProteinProteomicsProtein expressionHiPSC-neuronsExcitatory neuronsElectrophysiological statusDisease statesPhysiologyElectrophysiological dataNeuronsNeuronal levelUnveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity
Bodansky A, Yu D, Rallistan A, Kalaycioglu M, Boonyaratanakornkit J, Green D, Gauthier J, Turtle C, Zorn K, O'Donovan B, Mandel-Brehm C, Asaki J, Kortbawi H, Kung A, Rackaityte E, Wang C, Saxena A, de Dios K, Masi G, Nowak R, O'Connor K, Li H, Diaz V, Saloner R, Casaletto K, Gontrum E, Chan B, Kramer J, Wilson M, Utz P, Hill J, Jackson S, Anderson M, DeRisi J. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR-T therapies in autoimmunity. Journal Of Clinical Investigation 2024, 134: e180012. PMID: 38753445, PMCID: PMC11213466, DOI: 10.1172/jci180012.Peer-Reviewed Original ResearchB-cell maturation antigenImmunomodulatory therapyPlasma cell-targeted therapyCAR-T therapyCell-targeted therapyAutoantibody mediated diseasesCAR-TAnti-CD19Maturation antigenAutoantibody profileAutoreactive antibodiesTargeted therapyPlasma cellsAutoimmune diseasesAutoantibody repertoireTherapyMediated diseasesAutoantibodiesTherapeutic interventionsProteome-wideDisease statesDiseaseImmunological fingerprintPhIP-SeqMinimal effectNew Treatment Approaches in Non-Muscle-Invasive Bladder Cancer
Kim S, Lerner S. New Treatment Approaches in Non-Muscle-Invasive Bladder Cancer. 2024, 439-456. DOI: 10.1007/978-3-031-68505-7_21.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder cancerBCG-unresponsive NMIBCProbability of response to treatmentUS Food and Drug AdministrationNew treatment approachesResponse to treatmentFood and Drug AdministrationNuclear gradeBC casesDrug AdministrationHigh riskTreatment approachesDisease subtypesMorphological appearanceDisease statesCancerDrug developmentTreatment
2023
Highlights From the Annual Meeting of the American Epilepsy Society 2022
Valencia I, Alexander A, Andrade D, Arevalo-Astrada M, Rubiños C, Auer N, Bainbridge J, Baxendale S, Bartolomei F, Becker D, Berg A, Bernasconi A, Bernasconi N, Bernhardt B, Bhatnagar S, Blümcke I, Blumenfeld H, Buchanan G, Burdette D, Burneo J, Busch R, Chauvel P, Chin J, Clifford L, Conner K, Cook M, Conway J, Diaz-Arastia R, Drees C, French J, Ganguly T, Gelfand M, Glauser T, Gleichgerrcht E, Goldman A, Gonzalez-Martinez J, Gotman J, Grinspan Z, Guilfoyle S, Gupta G, Hammer M, Hartman A, Hentges K, Hogan R, Huh L, Hyslop A, Jobst B, Josephson C, Kelley S, Knupp K, Koepp M, Kothare S, Krook-Magnuson E, Kwasa J, La Vega-Talbott M, Lam A, Lee J, Lowenstein D, Maturu S, Mayor L, McDonald C, McKee H, McKhann G, Meador K, Mefford H, Michael E, Mikati M, Millichap J, Mitchell J, Myers L, Naritoku D, Neville K, Noebels J, O’Brien T, Oluigbo C, Patel A, Pavlova M, T. Paz J, Pennell P, Perry M, Perucca P, Pitkänen A, Plueger M, Pugh M, Quigg M, Reddy S, Ryan C, Reynolds T, Sajatovic M, Santana-Gomez C, Schommer L, Schuele S, Shellhaas R, Shrey D, Singh R, Sperling M, Suleman S, Templer J, Thom M, Trinka E, Varadkar S, Velez-Ruiz N, Velíšková J, Voskobiynyk Y, Wagner J, Wagnon J, Waller C, Waller J, Wang Z, Welborn M, Wirrell E, Jobst B. Highlights From the Annual Meeting of the American Epilepsy Society 2022. Epilepsy Currents 2023 DOI: 10.1177/15357597231187227.Peer-Reviewed Original ResearchAnti-seizure medicationsPathophysiology of epilepsyPost-traumatic epilepsyTraumatic brain injuryDifferent disease statesMechanism of actionPrepandemic timesNumber of physiciansBrain injuryEpilepsy careSeizure generationEpilepsy comorbiditiesEpilepsyReproductive healthHealth professionalsPatient advocatesVirtual offeringSatellite symposiumDisease statesBasic science lecturesReimbursement policiesGroup sessionsSmall group sessionsSessionsSkills workshopsCartilage-Related Collagens in Osteoarthritis and Rheumatoid Arthritis: From Pathogenesis to Therapeutics
Ouyang Z, Dong L, Yao F, Wang K, Chen Y, Li S, Zhou R, Zhao Y, Hu W. Cartilage-Related Collagens in Osteoarthritis and Rheumatoid Arthritis: From Pathogenesis to Therapeutics. International Journal Of Molecular Sciences 2023, 24: 9841. PMID: 37372989, PMCID: PMC10298547, DOI: 10.3390/ijms24129841.Peer-Reviewed Original ResearchConceptsRheumatoid arthritisArticular cartilageCourse of osteoarthritisNew biochemical markersDisease progressionPathogenic factorsCartilage damageDegradation of collagenBiochemical markersProgressive destructionClinical diagnosisMechanical injuryConnective tissueDisease statesRole of collagenCollagen productionLow immunogenicityFacilitate drug developmentArthritisDrug developmentOsteoarthritisBiomechanical propertiesMechanical functionCartilageCollagenThe Lymphatic System in Kidney Disease
Baker M, Cantley L. The Lymphatic System in Kidney Disease. Kidney360 2023, 4: e841-e850. PMID: 37019177, PMCID: PMC10371377, DOI: 10.34067/kid.0000000000000120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseLymphatic systemSetting of AKIKidney allograft rejectionNormal kidney functionImmune response modulationAllograft rejectionLymph nodesInflammatory infiltrateKidney functionImmune cellsTissue edemaNovel therapiesImmune surveillanceNumerous disease statesSystemic circulationFluid removalKidney tissueResident cellsTherapeutic potentialSurveillance cellsAKIDisease statesKidneyResponse modulationEvolutionarily conserved midbody remodeling precedes ring canal formation during gametogenesis
Price K, Tharakan D, Cooley L. Evolutionarily conserved midbody remodeling precedes ring canal formation during gametogenesis. Developmental Cell 2023, 58: 474-488.e5. PMID: 36898376, PMCID: PMC10059090, DOI: 10.1016/j.devcel.2023.02.008.Peer-Reviewed Original ResearchConceptsCanal formationStable intercellular bridgesGerm cell divisionMidbody ringTime-lapse imagingFemale germlineCell cytokinesisDrosophila malesRing canalsComplete cytokinesisKinase functionCell divisionCytokinesis eventsBroad functionsCytokinesisIntercellular bridgesExtensive remodelingMidbodyDrosophilaBiological systemsDisease statesImportant insightsGametogenesisGermlineProteinNIH HEAL Common Data Elements (CDE) implementation: NIH HEAL Initiative IDEA-CC
Adams M, Hurley R, Siddons A, Topaloglu U, Wandner L, Adams M, Arnsten J, Bao Y, Barry D, Becker W, Fiellin D, Fox A, Ghiroli M, Hanmer J, Horn B, Hurlocker M, Jalal H, Joseph V, Merlin J, Murray-Krezan C, Pearson M, Rogal S, Starrels J, Bachrach R, Witkiewitz K, Vasquez A. NIH HEAL Common Data Elements (CDE) implementation: NIH HEAL Initiative IDEA-CC. Pain Medicine 2023, 24: 743-749. PMID: 36799548, PMCID: PMC10321760, DOI: 10.1093/pm/pnad018.Peer-Reviewed Original ResearchConceptsClinical trialsClinical Trials NetworkCDE programsChronic painSecondary data analysisPainTrials NetworkDisease statesOpioidData standardsGeographical codingClinical researchHealing initiationData elementsNational InstituteTrialsDisordersFederal investmentInterventionStandard processDisorder researchSurveyed librariesCDELeveraging toolsNetwork alignment
2022
Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
Black E, Joo Y, Kabeche L. Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma. Biochemical Journal 2022, 479: 2345-2349. PMID: 36416754, PMCID: PMC9704517, DOI: 10.1042/bcj20220461.Peer-Reviewed Original ResearchConceptsReplication stressChk1 activityDNA damage response pathwayChk1 inhibitorsDNA replication stressInhibitor resistanceDamage response pathwayGenome instabilityPI3K/AktResponse pathwaysMolecular mechanismsNovel roleChk1Cancer therapyCancer developmentFemale fertilityDevelopment of resistancePathwayLethal levelsMultiple mechanismsAlternative pathwayNF-κBDrug resistanceIntriguing targetDisease statesA computational lens on menopause-associated psychosis
Fisher VL, Ortiz LS, Powers AR. A computational lens on menopause-associated psychosis. Frontiers In Psychiatry 2022, 13: 906796. PMID: 35990063, PMCID: PMC9381820, DOI: 10.3389/fpsyt.2022.906796.Peer-Reviewed Original ResearchEstrogen declinePsychotic symptomsNew-onset psychosisPathogenesis of psychosisPsychotic episodeNeural pathwaysSymptom presentationAge groupsImpair functioningProtective factorsPsychosisRisk periodSymptomsPatient-specific pathwaysDisease statesEarly adulthoodBiological correlatesNeural mechanismsEstrogenSex differencesEpisodesLatent stateExtreme distressMenopausePathogenesisCell death in development, maintenance, and diseases of the nervous system
Mercau ME, Patwa S, Bhat KPL, Ghosh S, Rothlin CV. Cell death in development, maintenance, and diseases of the nervous system. Seminars In Immunopathology 2022, 44: 725-738. PMID: 35508671, DOI: 10.1007/s00281-022-00938-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCell deathTissue-level responsesNervous system homeostasisNervous systemCentral nervous system tumorsMolecular modalitiesAcute brain injuryNervous system tumorsChronic neurodegenerative diseasesSystem homeostasisDead cellsNew therapeutic strategiesNeurodegenerative diseasesMechanisms of disposalGlial cellsNovel understandingAdult neurogenesisSystem tumorsBrain injuryPathological responseDisease statesTherapeutic strategiesCellsRecent studiesDeathFatty Acid Metabolism and T Cells in Multiple Sclerosis
Pompura SL, Hafler DA, Dominguez-Villar M. Fatty Acid Metabolism and T Cells in Multiple Sclerosis. Frontiers In Immunology 2022, 13: 869197. PMID: 35603182, PMCID: PMC9116144, DOI: 10.3389/fimmu.2022.869197.Peer-Reviewed Original ResearchConceptsT cell functionT cellsMultiple sclerosisSpecific lipid speciesEffector T cellsRegulatory T cellsCell functionT helper subsetsMetabolic programsT cell activationT cell transitionLipid speciesFatty acid metabolismTh subsetsHelper subsetsEffector stateBody of evidenceCell activationDisease settingsDisease statesFunctional phenotypeOrganismal levelAcid metabolismMetabolic remodelingNutrient availability
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply